Real-world homologous recombination repair (HRR) mutation testing patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in the United States (US).

被引：0
|
作者：
Barata, Pedro C.
Montgomery, Rachel
Last, Matthew
Gillespie-Akar, Liane
Nazari, Jonathan
Niyazov, Alexander
机构：
[1] Tulane Univ, New Orleans, LA USA
[2] Adelphi Real World, Bollington, England
[3] Pfizer Inc, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
99
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC)
    Chung, B. H.
    Huang, J.
    Uemura, H.
    Choi, Y. D.
    Ye, Z.
    Suzuki, H.
    Kang, T. W.
    He, D.
    Joung, J. Y.
    Brookman-May, S. D.
    McCarthy, S.
    Bhaumik, A.
    He, J.
    Mundle, S. D.
    Chowdhury, S.
    Agarwal, N.
    Ye, D.
    Chi, K. N.
    Uemura, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S649 - S650
  • [42] AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC).
    Rathkopf, Dana E.
    Chi, Kim N.
    Olmos, David
    Cheng, Heather H.
    Agarwal, Neeraj
    Graff, Julie N.
    Sandhu, Shahneen Kaur
    Hayreh, Vinny
    Lopez-Gitlitz, Angela
    Francis, Peter St. John
    Attard, Gerhardt
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [43] Real-world biomarker testing patterns in metastatic castration-resistant prostate cancer patients
    Blanc, Simon
    Adeboyeje, Gboyega
    Lee, Liam
    Gart, Mike
    Saunders, William
    Wang, Brandon
    Dave, Poras
    English, Sandy
    Varughese, Prateesh
    Sillah, Arthur
    CANCER RESEARCH, 2023, 83 (07)
  • [44] Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound
    Roubaud, G.
    Ozguroglu, M.
    Penel, N.
    Matsubara, N.
    Mehra, N.
    Kolinsky, M. P.
    Procopio, G.
    Feyerabend, S.
    Joung, J. Y.
    Gravis, G.
    Nishimura, K.
    Gedye, C.
    Padua, C.
    Shore, N.
    Thiery-Vuillemin, A.
    Gresty, C.
    Brickel, N.
    Burgents, J.
    Allen, A.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S515 - S516
  • [45] Real-world baseline characteristics and first-line (1L) treatment (Tx) in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC) by disease volume.
    Freedland, Stephen J.
    Hong, Agnes
    El-Chaar, Nader N.
    De Hoedt, Amanda Marie
    Kim, Janet
    Ramaswamy, Krishnan
    Gu, Lin
    Polascik, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] A cost-utility analysis of apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
    Parmar, Ambika
    Timilshina, Narhari
    Emmenegger, Urban
    Alibhai, Shabbir M. H.
    Smoragiewicz, Martin
    Sander, Beate
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2010 to 2019
    George, D. J.
    Sandin, R.
    Agarwal, N.
    Tagawa, S. T.
    Klaassen, Z.
    Bitting, R.
    Ramaswamy, K.
    Emir, B.
    Bland, C.
    Hong, A.
    Shi, L.
    Yang, H.
    Gao, W.
    Song, W.
    Freedland, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1175 - S1176
  • [48] Real-world time-to-castration resistance (CR) among patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) initiating apalutamide (APA), enzalutamide (ENZ), or abiraterone acetate (ABI) from an oncology database.
    Lowentritt, Benjamin H.
    Rossi, Carmine
    Du, Shawn
    Muser, Erik
    Kinkead, Frederic
    Waters, Dexter
    Lefebvre, Patrick
    Pilon, Dominic
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [49] Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study
    Barata, Pedro C.
    Leith, Andrea
    Ribbands, Amanda
    Montgomery, Rachel
    Last, Matthew
    Arondekar, Bhakti
    Ivanova, Jasmina
    Niyazov, Alexander
    ONCOLOGIST, 2023, 28 (09): : 780 - 789
  • [50] Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study
    Urabe, Fumihiko
    Imai, Yu
    Goto, Yuma
    Tashiro, Kojiro
    Hashimoto, Masaki
    Yoshihara, Kentaro
    Yamamoto, Shutaro
    Hara, Shuhei
    Miyajima, Keiichiro
    Fukuokaya, Wataru
    Enei, Yuki
    Iwatani, Kosuke
    Kayano, Sotaro
    Igarashi, Taro
    Aikawa, Koichi
    Yanagisawa, Takafumi
    Kimura, Shoji
    Tsuzuki, Shunsuke
    Murakami, Masaya
    Hata, Kenichi
    Shimomura, Tatsuya
    Yamada, Hiroki
    Miki, Jun
    Kimura, Takahiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024,
12345